Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of the Safety and Immunogenicity of a Single Dose of Intranasal Seasonal Trivalent Live-Attenuated Influenza Vaccine Among Children Aged 24 Through 59 Months in Bangladesh

NCT01625689 is registered in ClinicalTrials.gov with PATH Vaccine Solutions as lead sponsor.

NCT NCT01625689
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01625689 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of the Safety and Immunogenicity of a Single Dose of Intranasal Seasonal Trivalent Live-Attenuated Influenza Vaccine Among Children Aged 24 Through 59 Months in Bangladesh
Lead sponsor
PATH Vaccine Solutions
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2012
Completion date
February 28, 2013
Enrollment
309 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

influenza